EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Afucosylated anti-canine CD20 antibody combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in dogs with B-cell lymphoma

Takuya Mizuno, Kei Harada, Masanao Ichimata, Ryuzo Katayama, Yukinari Kato, Toshinori Shiga, Toshihiro Tsukui, Hiroto Toyoda, Eri Fukazawa, Fukiko Matsuyama, Masaya Igase, Tetsuya Kobayashi

Journal of Veterinary Internal Medicine · 2026

DOI: 10.1093/jvimsj/aalaf039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, 2026. Verfasst von Takuya Mizuno und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan. Hauptthemen laut MEDLINE: Dog Diseases, Antineoplastic Combined Chemotherapy Protocols, Lymphoma, B-Cell. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zenoaq Inc., Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

B-cell lymphoma in dogs is a common hematopoietic malignancy, often treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy, but long-term outcomes remain suboptimal. Although CD20 targeting has improved outcomes in humans with non-Hodgkin’s lymphoma, it remains challenging in dogs because of the lack of effective anti-CD20 antibodies. Hypothesis/Objectives We aimed to assess the safety, efficacy, and B-cell depletion kinetics of a novel afucosylated chimeric anti-canine anti-CD20 antibody (4E1-7-B_f) combined with CHOP chemotherapy in dogs with untreated B-cell lymphoma. Animals Thirteen client-owned dogs with high-grade B-cell lymphoma.

Methods

In this open-label, single-arm, single-center clinical trial, dogs received 4E1-7-B_f with CHOP chemotherapy. Treatment response was assessed using the Veterinary Cooperative Oncology Group criteria, whereas progression-free survival (PFS), overall survival (OS), and adverse events (AEs), and peripheral B-cell kinetics were evaluated.

Results

All 13 dogs achieved complete response (CR), with a median time to CR of 3 weeks. The median PFS and OS were 340 (95% confidence interval [CI], 87-417) and 458 (95% CI, 196–not estimable) days, respectively. The 1- and 2-year survival rates were 69.2% and 38.9%, respectively. Most AEs were mild to moderate. B-cell depletion lasted for > 200 days in most dogs, with some remaining B-cells deficient for over 300 days. Conclusions and clinical importance The combination of 4E1-7-B_f with CHOP chemotherapy showed promising efficacy and prolonged B-cell depletion. Although direct comparisons cannot be made because of the single-arm design, the results suggest a potential benefit over historical CHOP data. Additional randomized controlled trials are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesAntineoplastic Combined Chemotherapy ProtocolsLymphoma, B-CellAnimalsDogsCyclophosphamideDoxorubicinVincristinePrednisoneFemaleMaleAntigens, CD20

Stichwörter der Autor:innen

B-cell depletionantibody therapycancerchimeric antibodydogs

Substanzen

CyclophosphamideDoxorubicinVincristinePrednisoneAntigens, CD20

Autor:innen und Institutionen

  • Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi 753-8515, Japan.
  • Research Institute for Cell Design Medical Science, Yamaguchi University, Yamaguchi 753-8515, Japan.
  • Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa, Saitama 359-0023, Japan.
  • Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Miyagi 980-8575, Japan.
  • Zenoaq Inc., Fukushima 963-0102, Japan.

Förderung

  • Zenoaq Inc.
  • Japan Agency for Medical Research and Development

Zitieren

APA

Mizuno, T., Harada, K., Ichimata, M., Katayama, R., Kato, Y., Shiga, T., Tsukui, T., Toyoda, H., Fukazawa, E., Matsuyama, F., Igase, M., & Kobayashi, T. (2026). Afucosylated anti-canine CD20 antibody combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in dogs with B-cell lymphoma. Journal of Veterinary Internal Medicine. https://doi.org/10.1093/jvimsj/aalaf039

Vancouver

Mizuno T, Harada K, Ichimata M, Katayama R, Kato Y, Shiga T, et al. Afucosylated anti-canine CD20 antibody combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in dogs with B-cell lymphoma. Journal of Veterinary Internal Medicine. 2026. doi:10.1093/jvimsj/aalaf039

BibTeX
@article{Mizuno2026,
  author = {Mizuno, Takuya and Harada, Kei and Ichimata, Masanao and Katayama, Ryuzo and Kato, Yukinari and Shiga, Toshinori and Tsukui, Toshihiro and Toyoda, Hiroto and Fukazawa, Eri and Matsuyama, Fukiko and Igase, Masaya and Kobayashi, Tetsuya},
  title = {Afucosylated anti-canine CD20 antibody combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in dogs with B-cell lymphoma},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  doi = {10.1093/jvimsj/aalaf039}
}
Kostenlos starten →